Differences

This shows you the differences between two versions of the page.

--- allison_mcgeer [2022/01/28 00:10]
liam [Sinai Health System]
+++ allison_mcgeer [2024/12/27 22:31] (current)
liam
@@ Line 28: / Line 28: @@
 ==== National Collaborating Centre for Infectious Diseases ====
-As of at least 2015, McGeer is listed as a Partner at the National Collaborating Centre for Infectious Diseases.((//Partners.// National Collaborating Centre for Infectious Diseases. Retrieved January 16, 2022, from https://archive.ph/CC1RX)) The centre is hosted at the [[University of Manitoba]], and receives funding from the [[public_health_agencies:canada:Public Health Agency of Canada]].
+As of at least 2015, McGeer is listed as a Partner at the [[National Collaborating Centre for Infectious Diseases]].((//Partners.// National Collaborating Centre for Infectious Diseases. Retrieved January 16, 2022, from https://archive.ph/CC1RX)) The centre is hosted at the [[University of Manitoba]], and receives funding from the [[public_health_agencies:canada:Public Health Agency of Canada]].
 ==== Ontario COVID-19 Science Advisory Table ====
@@ Line 41: / Line 41: @@
 McGeer is an Infectious Disease Specialist and Senior Clinician Scientist at the [[Lunenfeld-Tanenbaum Research Institute]] of the [[Sinai Health System]] in Toronto, Ontario.((Public Health Ontario. //Ontario Immunization Advisory Committee (OIAC).// Retrieved November 9, 2021, from https://www.publichealthontario.ca/en/about/our-organization/external-advisory-committees/oiac)) ((Mount Sinai Hospital Department of Microbiology. //Staff Directory: Allison McGeer.// Mount Sinai Hospital. Retrieved November 11, 2021, from https://archive.ph/SrhEb)) The bottom of the McGeer's staff directory page carries a message bar reading "This website has been made possible through an unrestricted educational grant from [[pharmaceutical_companies:Pfizer]] Canada Inc."
+{{:3iqocpru_400x400.jpeg?200 |}}
 In her role at SHS, McGeer acted as a Local Principal Investigator for the "CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness" (CONCOR-1) study, funded by [[Canadian Blood
@@ Line 52: / Line 54: @@
   * [[https://archive.ph/8T0hg|December 23, 2020]]: Influenza Vaccine Effectiveness Against All-Cause Mortality Following Laboratory-Confirmed Influenza in Older Adults, 2010-2011 to 2015-2016 Seasons in Ontario, Canada((Chung, H., Buchan, S. A., Campigotto, A., Campitelli, M. A., Crowcroft, N. S., Dubey, V., Gubbay, J. B., Karnauchow, T., Katz, K., McGeer, A. J., McNally, J. D., Mubareka, S., Murti, M., Richardson, D. C., Rosella, L. C., Schwartz, K. L., Smieja, M., Zahariadis, G., & Kwong, J. C. (2020). //Influenza Vaccine Effectiveness Against All-Cause Mortality Following Laboratory-Confirmed Influenza in Older Adults, 2010–2011 to 2015–2016 Seasons in Ontario, Canada.// Clinical Infectious Diseases, 73(5), e1191–e1199. https://doi.org/10.1093/cid/ciaa1862))
     * Funded by the [[Canadian Institutes of Health Research]] (CIHR) and [[public_health_agencies:canada:Public Health Ontario]].
-    * McGeer reported Conflicts of Interest due to receiving “grants and personal fees” from [[pharmaceutical_companies:Sanofi]] Pasteur and [[pharmaceutical_companies:Merck]]; personal fees from [[pharmaceutical_companies:GlaxoSmithKine]]; and grants from [[pharmaceutical_companies:Seqirus]].
+    * McGeer reported Conflicts of Interest due to receiving “grants and personal fees” from [[pharmaceutical_companies:Sanofi]] Pasteur and [[pharmaceutical_companies:Merck]]; personal fees from [[pharmaceutical_companies:GlaxoSmithKline]]; and grants from [[pharmaceutical_companies:Seqirus]].
   * [[https://archive.ph/Ca7Ug|August 27, 2021]]: //Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers//((Abe, K. T., Hu, Q., Mozafarihashjin, M., Samson, R., Manguiat, K., Robinson, A., Rathod, B., Hardy, W. R., Wang, J. H., Iskilova, M., Pasculescu, A., Fazel-Zarandi, M., Li, A., Paterson, A., Chao, G., Green, K., Gilbert, L., Barati, S., Haq, N., . . . Gingras, A. C. (2021). //Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers.// medRxiv. Published. https://doi.org/10.1101/2021.08.06.21261721)) ((Ireland, N. (2021, September 28). COVID-19 vaccine boosters recommended for long-term care residents, national advisory committee says. CBC News. Retrieved November 20, 2021, from https://archive.ph/NXtRs))
@@ Line 60: / Line 62: @@
     * McGeer disclosed that she received funding from [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Medicago]], [[pharmaceutical_companies:Moderna]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:GlaxoSmithKline]], and [[pharmaceutical_companies:AstraZeneca]].
+===== External links =====
+  * [[https://wiki.whiteroseintelligence.com/en/Allison-McGeer|White Rose Wiki]]
+{{tag>Pro-narrative_scientists}}